Delving into the Latest Updates on Clover Biopharmaceuticals USA, Inc. with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

预防性疫苗	1

关联

1

项与 Clover Biopharmaceuticals USA, Inc. 相关的药物

Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)(Clover Biopharmaceuticals)

靶点-

作用机制-

在研机构

Clover Biopharmaceuticals USA, Inc.

原研机构

Clover Biopharmaceuticals AUS Pty Ltd.

在研适应症

呼吸道合胞体病毒感染

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

1

项与 Clover Biopharmaceuticals USA, Inc. 相关的临床试验

NCT06843317

/ Not yet recruiting临床1期

A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before

CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.

开始日期2025-03-03

申办/合作机构

Clover Biopharmaceuticals USA, Inc.

100 项与 Clover Biopharmaceuticals USA, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Clover Biopharmaceuticals USA, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Clover Biopharmaceuticals USA, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Clover Biopharmaceuticals USA, Inc. 相关的转化医学

登录后查看更多信息